

0

OI

Br

Ó

**Product Data Sheet** 

<sup>+</sup>HN

# Dihydro-β-erythroidine hydrobromide

Cat. No.:	B7030
CAS No.:	29734-68-7
Formula:	C16H21NO3·HBr
M.Wt:	356.26
Synonyms:	
Target:	Neuroscience
Pathway:	Nicotinic Receptor
Storage:	Desiccate at RT



<35.63mg/ml in H2O; <8.91mg/ml in DMSO

In Vitro	Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
		1 mM	2.8069 mL	14.0347 mL	28.0694 mL
		5 mM	0.5614 mL	2.8069 mL	5.6139 mL
		10 mM	0.2807 mL	1.4035 mL	2.8069 mL

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary

antagonist of nAChRs

IC<sub>50</sub> & Target

In Vitro

Cell Line:	Xenopus oocytes	
Preparation method:	The solubility of this compound in DMSO is > 10 mM. General tips for obtaining	
	a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or	
	shake it in the ultrasonic bath for a while. Stock solution can be stored below -	
	20 °C for several months.	
Reacting conditions:	300nM or 1 µM	
Applications:	At the concentration of 1 μM, Dihydro-β-erythroidine Hydrobromide almost	

1 | www.apexbt.com

		completely blocked the $\alpha4\beta4$ subunit but showed little effect on the $\alpha3\beta4$		
		subunit. However, the blockade effect of Dihydro- $\beta$ -erythroidine Hydrobromide		
		on the $\alpha 4\beta 4$ subunit could be reversed by increasing the agonist concentration.		
		In the presence of 300 nM Dihydro- $\beta$ -erythroidine Hydrobromide, the current		
		response of $\alpha4\beta4\text{-expressing}$ oocytes to 5 $\mu\text{M}$ and 500 $\mu\text{M}$ ACh were 36.0 $\pm$		
		9.0 % and 97.1 $\pm$ 9.6 % of the response to ACh alone, respectively.		
	Animal experiment			
In Vivo	Animal models:	A nicotine-induced hypothermia mouse model		
	Dosage form:	0, 1.8, 3.6, 7.2 or 10.8 μmol/kg; s.c.		
	Applications:	In a nicotine-induced hypothermia mouse model, Dihydro-β-erythroidine		
		Hydrobromide dose-dependently attenuated hypothermia, with the AD50 value		
		of 6.2 µmol/kg. But it did not have a significant effect on the		
		non-nicotine-induced increase in body temperature at the inducated doses.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
		slightly differ with the theoretical value. This is caused by an experimental		
		system error and it is normal.		

## **Product Citations**

See more customer validations on www.apexbt.com.

#### References

[1]. Harvey SC, Maddox FN, Luetje CW. Multiple determinants of dihydro-beta-erythroidine sensitivity on rat neuronal nicotinic receptor alpha subunits. J Neurochem. 1996 Nov;67(5):1953-9.

[2]. Damaj MI, Welch SP, Martin BR. In vivo pharmacological effects of dihydro-beta-erythroidine, a nicotinic antagonist, in mice. Psychopharmacology (Berl). 1995 Jan;117(1):67-73.

#### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

2 | www.apexbt.com



### APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com